Skip to main content
. 2013 Dec 10;22(3):511–521. doi: 10.1038/mt.2013.250

Figure 3.

Figure 3

Functional improvements in TrJ mice following i.m. injection of ssAAV1.CMV.NT-3 (1 × 1011vg) compared to PBS control group. (a) Grip strength in the left hindlimbs harboring the regenerating sciatic nerves from NT-3 group show significant improvement compared to the PBS-treated TrJ at the 15-week postcrush time point, 18 weeks after vector injection (n = 12 in each group). In a parallel group without nerve crush, the NT-3 gene therapy group performed significantly better starting around 10 weeks in left hindlimb (b) and simultaneous bilateral hindlimb grip (c) strength measures compared to PBS controls (n = 14 in each group). (d) Rotarod performance collected between 20 and 40 weeks postinjection shows a continuous improvement in the NT-3-treated group (AAV1.NT-3 group, n = 10; PBS group, n = 9). Error bars represent standard error. Multiple t-test one per row was performed; *P < 0.05, **P < 0.001.